Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation
Background: There is little evidence of the efficacy and safety of dabigatran in Japanese patients with non-valvular atrial fibrillation (NVAF). Methods and Results: We evaluated 300 consecutive patients with NVAF (68±11 years old, 209 men, 180 paroxysmal) who received 220 mg/day (203 patients) or 3...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-02-01
|
| Series: | Journal of Arrhythmia |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S188042761300094X |
| _version_ | 1819055711875760128 |
|---|---|
| author | Koji Miyamoto Takeshi Aiba Ikutaro Nakajima Yuko Yamada Hideo Okamura Takashi Noda Kazuhiro Satomi Masaharu Ishihara Toshihisa Anzai Satoshi Yasuda Hisao Ogawa Shiro Kamakura Wataru Shimizu |
| author_facet | Koji Miyamoto Takeshi Aiba Ikutaro Nakajima Yuko Yamada Hideo Okamura Takashi Noda Kazuhiro Satomi Masaharu Ishihara Toshihisa Anzai Satoshi Yasuda Hisao Ogawa Shiro Kamakura Wataru Shimizu |
| author_sort | Koji Miyamoto |
| collection | DOAJ |
| description | Background: There is little evidence of the efficacy and safety of dabigatran in Japanese patients with non-valvular atrial fibrillation (NVAF).
Methods and Results: We evaluated 300 consecutive patients with NVAF (68±11 years old, 209 men, 180 paroxysmal) who received 220 mg/day (203 patients) or 300 mg/day dabigatran (97 patients) at our hospital. Most patients (84%) had lower CHADS2 (congestive heart failure, hypertension, age>75 years, diabetes, stroke/transient ischemic attack) scores of 0 (n=60), 1 (n=114), or 2 (n=78) and lower HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition) scores of 0 (n=39), 1 (n=114), or 2 (n=103). The estimated creatinine clearance was 77±24 mL/min, which was inversely correlated to age (r2=0.48, p<0.0001). Activated partial thromboplastin time was 42±9 s but was not dependent on sampling time. During follow-up of 263±160 days, an ischemic stroke occurred in 1 patient (0.3%), but no systemic embolism was observed. Some adverse events were reported for 70 (23%) patients, such as dyspepsia (n=42, 14%) or minor bleeding complications (n=11, 4%) resulting in discontinuation of dabigatran for 39 patients. However, no major complications were observed, and no patient died from adverse events or because of cardiovascular or stroke events.
Conclusions: Dabigatran is safe and useful for the prevention of ischemic strokes in Japanese NVAF patients, but additional care should be taken for elderly patients. |
| first_indexed | 2024-12-21T13:11:52Z |
| format | Article |
| id | doaj.art-2afa811ec6454d78a37d86d6b9ddee27 |
| institution | Directory Open Access Journal |
| issn | 1880-4276 |
| language | English |
| last_indexed | 2024-12-21T13:11:52Z |
| publishDate | 2014-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Arrhythmia |
| spelling | doaj.art-2afa811ec6454d78a37d86d6b9ddee272022-12-21T19:02:50ZengWileyJournal of Arrhythmia1880-42762014-02-01301586410.1016/j.joa.2013.04.010Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillationKoji Miyamoto0Takeshi Aiba1Ikutaro Nakajima2Yuko Yamada3Hideo Okamura4Takashi Noda5Kazuhiro Satomi6Masaharu Ishihara7Toshihisa Anzai8Satoshi Yasuda9Hisao Ogawa10Shiro Kamakura11Wataru Shimizu12Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, JapanBackground: There is little evidence of the efficacy and safety of dabigatran in Japanese patients with non-valvular atrial fibrillation (NVAF). Methods and Results: We evaluated 300 consecutive patients with NVAF (68±11 years old, 209 men, 180 paroxysmal) who received 220 mg/day (203 patients) or 300 mg/day dabigatran (97 patients) at our hospital. Most patients (84%) had lower CHADS2 (congestive heart failure, hypertension, age>75 years, diabetes, stroke/transient ischemic attack) scores of 0 (n=60), 1 (n=114), or 2 (n=78) and lower HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition) scores of 0 (n=39), 1 (n=114), or 2 (n=103). The estimated creatinine clearance was 77±24 mL/min, which was inversely correlated to age (r2=0.48, p<0.0001). Activated partial thromboplastin time was 42±9 s but was not dependent on sampling time. During follow-up of 263±160 days, an ischemic stroke occurred in 1 patient (0.3%), but no systemic embolism was observed. Some adverse events were reported for 70 (23%) patients, such as dyspepsia (n=42, 14%) or minor bleeding complications (n=11, 4%) resulting in discontinuation of dabigatran for 39 patients. However, no major complications were observed, and no patient died from adverse events or because of cardiovascular or stroke events. Conclusions: Dabigatran is safe and useful for the prevention of ischemic strokes in Japanese NVAF patients, but additional care should be taken for elderly patients.http://www.sciencedirect.com/science/article/pii/S188042761300094XDabigatranAtrial fibrillationEfficacySafetyJapanese |
| spellingShingle | Koji Miyamoto Takeshi Aiba Ikutaro Nakajima Yuko Yamada Hideo Okamura Takashi Noda Kazuhiro Satomi Masaharu Ishihara Toshihisa Anzai Satoshi Yasuda Hisao Ogawa Shiro Kamakura Wataru Shimizu Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation Journal of Arrhythmia Dabigatran Atrial fibrillation Efficacy Safety Japanese |
| title | Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation |
| title_full | Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation |
| title_fullStr | Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation |
| title_full_unstemmed | Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation |
| title_short | Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation |
| title_sort | efficacy and safety of novel anticoagulant dabigatran in clinical practice for japanese patients with non valvular atrial fibrillation |
| topic | Dabigatran Atrial fibrillation Efficacy Safety Japanese |
| url | http://www.sciencedirect.com/science/article/pii/S188042761300094X |
| work_keys_str_mv | AT kojimiyamoto efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT takeshiaiba efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT ikutaronakajima efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT yukoyamada efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT hideookamura efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT takashinoda efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT kazuhirosatomi efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT masaharuishihara efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT toshihisaanzai efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT satoshiyasuda efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT hisaoogawa efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT shirokamakura efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation AT watarushimizu efficacyandsafetyofnovelanticoagulantdabigatraninclinicalpracticeforjapanesepatientswithnonvalvularatrialfibrillation |